MARGARET FASO

Lobbying related to federal legislation and regulations affecting employer-sponsored health coverage, including the Patients Deserve Price Tags Act and other proposals to enhance health care price transparency, employer access to claims and encounter data, and reporting requirements necessary for ERISA plan sponsors to fulfill fiduciary obligations. Lobbying related to pharmacy benefit manager (PBM) reform, including transparency and reporting requirements, prohibition of spread pricing practices, pass-through of rebates and fees to employer-sponsored health plans, audit rights, and other measures intended to reduce prescription drug costs and improve accountability. Lobbying related to reform and oversight of the 340B Drug Pricing Program, including reporting and transparency requirements for covered entities and contract pharmacies, program integrity measures, and policies affecting employer-sponsored health plan costs, biosimilar adoption, and commercial market competition. Lobbying related to hospital price transparency requirements, site-neutral payment policies, anti-competitive contracting practices, and other federal policies intended to improve health care affordability, competition, and transparency for employers and consumers. Lobbying related to implementation and reform of the Independent Dispute Resolution (IDR) process established under the No Surprises Act, including administrative efficiency, compliance, payment determination methodologies, and impacts on employer-sponsored health plans. Lobbying related to mental health parity requirements, employer-sponsored health plan compliance obligations, and other federal health care policies affecting employer health benefit programs.

S.2355, the Patients Deserve Price Tags Act; all provisions related to enhancing hospital and PBM transparency requirements to assist ERISA plan sponsors in fulfilling fiduciary duties; specifically provisions impacting employer-sponsored health plan reporting of cost and quality data to plan participants. H.R. 4317, the PBM Reform Act; provisions related to pharmacy benefit manager transparency and reporting requirements for ERISA group health plans; specifically sections regarding the 'ban on spread pricing' and the mandatory pass-through of rebates to employer plan sponsors. Lobbying related to reform of the 340B program like H.R. 3290, the 340B Transparency Act; provisions related to reporting requirements for covered entities; specifically issues concerning the impact of 340B contract pharmacy arrangements on employer-sponsored health plan costs and commercial market discounts. Lobbying related to the implementation and reform of the Independent Dispute Resolution (IDR) process established by the No Surprises Act; specifically advocating for improvements to the IDR Operations Rule to enhance administrative efficiency, reduce backlogs, and ensure fair payment determinations for ERISA plan sponsors.

Issues related to employer sponsored health care.